Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nyse  >  Allergan plc    AGN   IE00BY9D5467

My previous session
Most popular
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets

Allergan : Receives Refusal to File Letter from FDA for Vraylar® cariprazine Supplemental New Drug Application sNDA for the Treatment of Negative...

share with twitter share with LinkedIn share with facebook
share via e-mail
10/05/2017 | 05:46pm CEST

Allergan Receives Refusal to File Letter from FDA for Vraylar® cariprazine Supplemental New Drug Application sNDA for the Treatment of Negative Symptoms in Schizophrenia

By a News Reporter-Staff News Editor at Mental Health Weekly Digest -- Allergan plc (NYSE: AGN) announced that it received a Refusal to File (RTF) letter from the U.S. Food and Drug Administration (FDA) regarding its Supplemental New Drug Application (sNDA) for Vraylar (cariprazine) for treatment of negative symptoms associated with schizophrenia in adult patients. VRAYLAR is an oral, once daily atypical antipsychotic approved in the United States for the treatment of schizophrenia and the acute treatment of adult patients with manic or mixed episodes associated with bipolar I disorder (see also Allergan plc).

Upon its preliminary review, FDA determined that the sNDA for treatment of negative symptoms was not sufficiently complete to permit a substantive review.

"We are disappointed with the FDA decision on our submission. We will request a meeting with FDA to discuss and determine our next steps. Vraylar is an important treatment option for patients suffering from bipolar I disorder and schizophrenia. We remain committed to our mental health program and to cariprazine and its potential as a treatment option for patients suffering from negative symptoms associated with schizophrenia," said David Nicholson Ph.D., Chief Research & Development Officer, Allergan.

Schizophrenia is a chronic and disabling disorder that includes positive symptoms (i.e. hallucinations, delusions and thought disorders) and negative symptoms (i.e. loss of motivation and social withdrawal). These symptoms are strongly associated with long term morbidity, poor psychosocial functioning and considerable social and economic costs.

Cariprazine is approved in Europe for the treatment of schizophrenia. The approval includes data from the 460-patient negative symptoms study which was conducted by Gedeon Richter and published in the Lancet on February 6, 2017.

The Company will seek immediate guidance, and is in the process of planning a meeting with the FDA, to respond to the issues, and to seek clarification of what additional information will be required.

Keywords for this news article include: Psychiatry, FDA Actions, Allergan plc, Schizophrenia, Mental Health Diseases and Conditions, Government Agencies Offices and Entities.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ALLERGAN PLC
09/20ALLERGAN : to Acquire Bonti Adding New Neurotoxin Programs to Medical Aesthetics..
09/20ALLERGAN : Unveils Spotlyte™, A First-In-Category Digital Hub Designed To ..
09/20ALLERGAN : to Host Medical Aesthetics Day Event on September 14, 2018
09/20ALLERGAN : Study Results from Allergan Update Understanding of Acute Kidney Inju..
09/20ALLERGAN : Teams Up with Actor Scott Eastwood to Encourage Recognition of World ..
09/20ALLERGAN : Announces Results of Higher Dose BOTOX Cosmetic (onabotulinumtoxinA) ..
09/19ALLERGAN : Announces Plans to Build First Medical Aesthetics Innovation Center i..
09/19ALLERGAN : Announces Results of Higher Dose BOTOX Cosmetic for the Treatment of ..
09/19ALLERGAN : Highlights Key Growth Drivers for Medical Aesthetics
09/19SOSEI : Allergan to delay trials of dementia candidate
More news
News from SeekingAlpha
09/18Allergan Snaps Up Early Stage Startup, Goes Back To Its Aesthetic Roots 
09/18YOUR DAILY PHARMA SCOOP : Alnylam Regains, Karyopharm Positive, Teva Approved 
09/18Senate passes opioid crisis bill 
09/17House nixes drug prices in TV ads 
09/14Allergan's Botox shows treatment benefit at higher doses 
Financials ($)
Sales 2018 15 523 M
EBIT 2018 7 411 M
Net income 2018 -1 186 M
Debt 2018 23 063 M
Yield 2018 1,44%
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 5,70x
EV / Sales 2019 5,46x
Capitalization 65 346 M
Duration : Period :
Allergan plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALLERGAN PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 212 $
Spread / Average Target 9,9%
EPS Revisions
Brenton L. Saunders Chairman, President & Chief Executive Officer
Wayne R. Swanton Executive Vice President-Global Operations
Matthew M. Walsh Chief Financial Officer & Executive Vice President
C. David Nicholson Chief Research & Development Officer
Charles Hugh-Jones Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
ALLERGAN PLC17.69%65 346
JOHNSON & JOHNSON0.53%380 898
PFIZER19.44%256 467
NOVARTIS-0.56%216 108
ROCHE HOLDING LTD.-4.65%210 186
MERCK AND COMPANY25.79%188 241